ZEGALOGUE (AUTOINJECTOR) Drug Patent Profile
✉ Email this page to a colleague
When do Zegalogue (autoinjector) patents expire, and what generic alternatives are available?
Zegalogue (autoinjector) is a drug marketed by Zealand Pharma and is included in one NDA. There are two patents protecting this drug.
This drug has thirty-three patent family members in twenty-four countries.
The generic ingredient in ZEGALOGUE (AUTOINJECTOR) is dasiglucagon hydrochloride. Two suppliers are listed for this compound. Additional details are available on the dasiglucagon hydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Zegalogue (autoinjector)
Zegalogue (autoinjector) will be eligible for patent challenges on March 22, 2025. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ZEGALOGUE (AUTOINJECTOR)?
- What are the global sales for ZEGALOGUE (AUTOINJECTOR)?
- What is Average Wholesale Price for ZEGALOGUE (AUTOINJECTOR)?
Summary for ZEGALOGUE (AUTOINJECTOR)
International Patents: | 33 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
DailyMed Link: | ZEGALOGUE (AUTOINJECTOR) at DailyMed |
![ZEGALOGUE (AUTOINJECTOR) drug patent expirations Drug patent expirations by year for ZEGALOGUE (AUTOINJECTOR)](/p/graph/s/t/ZEGALOGUE_(AUTOINJECTOR)-patent-expirations.png)
Pharmacology for ZEGALOGUE (AUTOINJECTOR)
Drug Class | Antihypoglycemic Agent |
Mechanism of Action | Glucagon Receptor Agonists |
Physiological Effect | Increased Glycogenolysis |
US Patents and Regulatory Information for ZEGALOGUE (AUTOINJECTOR)
ZEGALOGUE (AUTOINJECTOR) is protected by two US patents and one FDA Regulatory Exclusivity.
Patents protecting ZEGALOGUE (AUTOINJECTOR)
Glucagon analogues
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING DIABETIC HYPOGLYCEMIA
FDA Regulatory Exclusivity protecting ZEGALOGUE (AUTOINJECTOR)
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Zealand Pharma | ZEGALOGUE (AUTOINJECTOR) | dasiglucagon hydrochloride | SOLUTION;SUBCUTANEOUS | 214231-002 | Mar 22, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Zealand Pharma | ZEGALOGUE (AUTOINJECTOR) | dasiglucagon hydrochloride | SOLUTION;SUBCUTANEOUS | 214231-002 | Mar 22, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Zealand Pharma | ZEGALOGUE (AUTOINJECTOR) | dasiglucagon hydrochloride | SOLUTION;SUBCUTANEOUS | 214231-002 | Mar 22, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ZEGALOGUE (AUTOINJECTOR)
See the table below for patents covering ZEGALOGUE (AUTOINJECTOR) around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 6534927 | ⤷ Sign Up | |
Hong Kong | 1210787 | 胰高血糖素類似物 (GLUCAGON ANALOGUES) | ⤷ Sign Up |
New Zealand | 704043 | Glucagon analogues | ⤷ Sign Up |
South Korea | 20150032912 | GLUCAGON ANALOGUES | ⤷ Sign Up |
Japan | 2019187419 | グルカゴン類似体 (GLUCAGON ANALOGS) | ⤷ Sign Up |
Philippines | 12015500115 | GLUCAGON ANALOGUES | ⤷ Sign Up |
Malaysia | 170671 | GLUCAGON ANALOGUES | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |